Janssen Sciences Ireland UC

Intent: To adopt a holistic national strategy for the life sciences sector in Ireland which aims to realise benefits both to economic development and public health.

Methods: Informal communication

Intent: To promote Irish input into the development of the EU Strategy for the Life Sciences in 2025.::To support pharmaceutical innovation and competitiveness at European level by maintaining the existing baselines of IP and incentives for new medicines in the context of the revision of the general pharmaceutical legislation.

Methods: Meeting, Informal communication

Intent: To adopt a holistic national strategy for the life sciences sector which aims for both public health and economic benefits.::To protect the existing IP baselines and incentives framework in the context of the revision of the EU pharmaceutical legislation.::To improve speed of patient access to new medicines in Ireland.

Methods: Informal communication, Email, Submission

Intent: To introduce new Ministers to J&J and highlight its positive contribution to public health and the Irish economy.::To advance the adoption of a holistic national strategy for the life sciences sector, aiming for benefits both to public health and economic development.::To welcome the Government commitment to achieve patient access as quickly as possible and to reduce the timelines for patients in Ireland to access innovative medicines through reform of the reimbursement system.::To establish a platform for ongoing stakeholder collaboration with Government on medicines reimbursement.::To welcome the Government's commitment to support IP rights for medicines to drive innovation and competitiveness and to request that this be reflected in Irish positions at European level.

Methods: Letter, Informal communication

Intent: To encourage Fianna Fáil support for advancement of the promised national life sciences strategy and encourage collaboration with the health service in this matter.::To speed up patient access to innovative medicines through reform of the reimbursement process for new treatments.

Methods: Meeting, Informal communication

Intent: To discuss Ireland's continued support for the life sciences sector and J&J's long-term investments in Ireland.::To maintain open lines of communication between the Irish government and J&J and discuss resiliency across global supply chains.

Methods: Phone call

Intent: To signal the importance of successful outcomes to the EU pharma package to the industry in Ireland::To communicate the long-term potential for the development of the life sciences industry in Ireland

Methods: Email

Intent: To highlight the need for an increased focus on competitiveness, and to develop both Ireland and the EU's investment climate for the life sciences industry post-Draghi Report::To highlight industry concerns arising from EU policy files including the EU Pharma Package (proposed cuts to regulatory data protection), the Urban Wastewater Treatment Directive, and local medicines reimbursement challenges.::To highlight supply chain concerns for the industry on medicine shortages and the Critical Medicines Act and to highlight recommendations from the Critical Medicines Alliance.::To adopt an appropriate approach to civil justice reform at EU level, protecting Europe's legal framework through Third Party Litigation legislation.

Methods: Meeting

Intent: To promote the development and adoption by the new Government of a national life sciences strategy

Methods: Informal communication, Email, Submission

Intent: To highlight the risks associated with Third Party Litigation Funding in the context of the Products Liability Directive::To encourage EU regulation on this area and the imposition of a transparency obligation with respect to TPLF

Methods: Informal communication